Target intelligence / Profile preview

Peroxisomal beta-oxidation pathway (liver)

Molecular classification
Other (metabolic pathway), Enzyme (for individual components, e.g., acyl-CoA oxidase)
01

Overview

The **liver peroxisomal beta-oxidation pathway** is a series of enzymatic reactions occurring within hepatic peroxisomes, primarily responsible for shortening very long-chain, branched fatty acids, and some prostaglandins/leukotrienes. These fatty acids cannot be metabolized by mitochondria due to their length, so peroxisomes initiate their breakdown, ultimately producing acetyl-CoA and hydrogen peroxide (H2O2)[2][1]. Key enzymes include **acyl-CoA oxidase (Acox1)**, which performs the initial oxidation, and **PPARα** regulates the expression of these enzymes[1][2][4]. The pathway is distinct from mitochondrial beta-oxidation, as it is not directly coupled to ATP synthesis and contributes to the production of reactive oxygen species. Dysfunction or genetic deficiency of pathway enzymes can drive fatty liver pathology, steatohepatitis, and overall dysregulation of metabolism and immune responses[3][1].

Other names
Peroxisomal fatty acid beta-oxidationperoxisomal β-oxidation
02

Mechanism of action

Induction of pathway enzymes (by activating PPARα, increasing fatty acid oxidation and decreasing lipid accumulation)

03

Biological functions

Fatty acid metabolismEnergy productionChain-shortening of very long chain fatty acidsReactive oxygen species production (via H2O2)Regulation of whole body metabolismModulation of immune response and inflammation
04

Disease associations

Metabolic disease (e.g., fatty liver disease/NAFLD/steatohepatitis)Liver disease (steatosis, steatohepatitis)Genetic disorders (enzyme deficiencies)
05

Safety considerations

Excessive H2O2 and reactive oxygen species production (can lead to oxidative damage)Hepatic inflammation and injury with enzyme deficiencies or dysregulationSystemic inflammation and immune dysregulation (as seen in mouse models)
06

Interacting drugs

Hypolipidemic drugs (e.g., clofibrate induces peroxisomal β-oxidation)

1 more in the full profile.

07

Biomarkers

Acox1 enzyme activity/levelsReactive oxygen species (e.g., H2O2)Liver transaminases (ALT, indicators of hepatocellular injury)4-hydroxynonenal (marker of lipid peroxidation)

Beyond the preview

Go deeper on Peroxisomal beta-oxidation pathway (liver).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peroxisomal beta-oxidation pathway (liver).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call